CWBR
- CohBar, Inc.
()
Overview
Company Summary
CohBar, Inc. (CWBR) is a biotechnology company that specializes in the development of innovative therapies targeting age-related diseases. The company focuses on the research and development of mitochondrial peptide-based therapeutics, which are small proteins that play a crucial role in the regulation of cellular functions and energy production.
CohBar's approach is to utilize the potential of mitochondria, often referred to as the powerhouses of the cell, to develop novel drugs that can address a wide range of age-related diseases. By targeting mitochondrial function, they aim to address the underlying causes of these diseases rather than just managing symptoms.
The company's research and development efforts are primarily focused on identifying and optimizing mitochondrial peptides with therapeutic properties. They utilize advanced technologies and computational biology approaches to identify potential candidates and then conduct preclinical studies to evaluate their safety and efficacy.
CohBar's pipeline includes several drug candidates that are being developed for diseases such as obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and even cancer. These potential therapies target key processes involved in metabolic regulation, inflammation, and tissue repair.
Through strategic collaborations and partnerships, CohBar also seeks to advance its drug candidates towards clinical trials and potentially commercialization. The ultimate goal is to develop therapies that can improve the quality of life for individuals suffering from age-related diseases, addressing significant unmet medical needs in the process.
In summary, CohBar, Inc. is a biotechnology company that specializes in the development of mitochondrial peptide-based therapeutics to treat age-related diseases. They focus on addressing the underlying causes of these conditions and have a pipeline of potential drug candidates targeting various disorders, ranging from metabolic diseases to cancer.